Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
19 studies found for:    " March 21, 2012":" April 20, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed
Has Results 		D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: D/C/F/TAF;   Drug: DRV;   Drug: COBI;   Drug: FTC/TDF;   Drug: D/C/F/TAF Placebo;   Drug: DRV Placebo;   Drug: COBI Placebo;   Drug: FTC/TDF Placebo
2 Terminated The Mochudi Prevention Project ART Protocol
Condition: HIV Infections
Intervention: Drug: highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine
3 Unknown † Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
Conditions: Human Immunodeficiency Virus (HIV);   Tuberculosis (TB);   Latent Tuberculosis Infection (LTI)
Intervention: Drug: Isoniazid
4 Completed Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Condition: HIV Infection
Interventions: Drug: Tenofovir, Emtricitabine, Lopinavir/r;   Drug: Tenofovir, Emtricitabine, Raltegravir
5 Active, not recruiting Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-MAG vaccine;   Biological: IL-12 pDNA adjuvant;   Biological: VSV HIV gag vaccine;   Biological: Placebo;   Device: Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
6 Active, not recruiting Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
Condition: HIV Infections
Interventions: Biological: GEO-D03 DNA vaccine;   Biological: MVA/HIV62B (MVA62B) vaccine;   Biological: Placebo for GEO-D03 DNA;   Biological: Placebo for MVA62B:
7 Unknown † Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Condition: HIV
Intervention: Drug: Lopinavir/ritonavir 800 mg / 200mg
8 Completed Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda
Conditions: HIV;   Tuberculosis
Intervention: Other: Cellular Phone Text Message Formats
9 Recruiting Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Condition: HIV
Intervention: Drug: Tesamorelin for injection
10 Completed Experimental Analysis of HIV Risk Assessment Reactivity in South African Clinics
Condition: HIV Prevention and Assessment Reactivity
Interventions: Behavioral: Detailed baseline interview, enhanced HIV intervention;   Behavioral: General baseline interview, enhanced HIV intervention;   Behavioral: No baseline interview, enhanced HIV intervention;   Behavioral: Detailed baseline interview, standard of care intervention;   Behavioral: General baseline interview, standard of care intervention;   Behavioral: No baseline interview, standard of care intervention
11 Unknown †
Has Results 		Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg twice daily;   Drug: dolutegravir placebo twice daily;   Drug: Open-label dolutegravir 50mg twice daily
12 Completed A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: DTG;   Drug: BCV;   Drug: TVR
13 Terminated A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy
Condition: HIV-associated Myelopathy
Interventions: Drug: Intravenous Immunoglobulin;   Drug: Placebo
14 Completed
Has Results 		Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
Conditions: Hepatitis C;   HIV
Interventions: Drug: SOF;   Drug: EFV/FTC/TDF;   Drug: EFV;   Drug: ZDV/3TC;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: DRV;   Drug: RAL;   Drug: PEG;   Drug: RBV
15 Completed
Has Results 		The Rilpivirine Cerebrospinal-fluid (CSF) Study
Condition: HIV
Intervention: Drug: Rilpivirine
16 Recruiting Vascular Subphenotypes of Lung Disease in HIV & COPD
Condition: Pulmonary Artery Hypertension
Intervention:
17 Terminated
Has Results 		Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection
Condition: Cryptococcal Infection Disseminated
Interventions: Drug: Flucytosine and fluconazole;   Drug: Fluconazole
18 Active, not recruiting HIV Prevention Intervention for Young Transgender Women
Condition: Sexual Transmission of Infection
Interventions: Behavioral: HIV prevention intervention;   Behavioral: Diet and Nutrition
19 Recruiting Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
Conditions: Anal Cancer;   Cervical Cancer;   Lung Cancer;   Lymphoma
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: medical chart review
To Top

† Indicates status has not been verified in more than two years